The federal proceeding to more broadly reclassify marijuana has encountered another delay, this time over a government watchdog’s examination of how drug-scheduling decisions are made. Drug Enforcement Administration Chief Administrative Law Judge Derek C. Julius issued a stay on September 29 while considering a request to add a newly released Government Accountability Office report to the hearing record. The order interrupts a case that had already completed its summer evidentiary hearing and moved through post-hearing briefing, leaving the judge’s recommended decision as the next anticipated major step.
The immediate dispute concerns whether the report belongs in the record and whether participants should receive another opportunity to address its significance. Julius has not ruled against Schedule III, invalidated the government’s scientific evidence or ordered agencies to complete policy reforms before proceeding. Nevertheless, the pause creates fresh uncertainty around a closely watched federal initiative. It also places a consequential question before the tribunal: how much weight should shortcomings in an agency’s written procedures carry when assessing a particular scheduling recommendation developed through those procedures?
What the Judge’s Order Actually Does
The September 29 order directs the government to respond by October 13 to a motion seeking admission of the GAO report and supplemental briefing. DEA’s response may run up to 20 pages. Other designated participants may respond under the same deadline and specifications, although they are not required to do so. The case remains stayed pending resolution of the motion. October 13 is therefore a filing deadline, rather than a promised date for a rescheduling decision or an automatic end to the pause. The distinction matters for anyone trying to read the next procedural milestone as a firm implementation timetable.
The hearing on the merits ran from June 29 through July 15, meaning the order arrives after testimony rather than before an upcoming hearing. Julius is deciding whether to expand an already developed administrative record before completing his recommendation. His role must also be distinguished from that of DEA’s leadership: an administrative law judge’s recommended decision is a step toward agency action, rather than the final rule itself. Even a recommendation supporting Schedule III would leave further agency decision-making ahead. The new dispute adds uncertainty to that remaining sequence without establishing its ultimate outcome.
What the Federal Watchdog Found
Released September 23, GAO’s report examined scheduling actions involving 208 substances from 2020 through 2025. HHS evaluations were required for 95, and DEA considered them in every case. Among those substances, all 84 completed final scheduling decisions matched HHS recommendations; 11 remained under extended temporary scheduling orders. The review also identified policy gaps. DEA lacked comprehensive written roles, responsibilities and procedures for scheduling, while FDA lacked procedures explaining how staff should conduct evaluations and develop recommendations. An FDA agreement for consulting the National Institute on Drug Abuse was more than 40 years old and outdated.
GAO recommended written policies for DEA and FDA and an updated FDA–NIH agreement; the agencies concurred. Its findings distinguish successful coordination in the reviewed decisions from weaknesses in documenting how that coordination should work. Written procedures can preserve expertise when experienced staff leave and make expectations clearer across offices. The report did not conclude that marijuana belongs in Schedule I or that HHS’s recommendation should be withdrawn. Turning its institutional findings into a reason to reject this particular proposal requires an additional argument about their relevance to the marijuana evidence and applicable legal standards.
Why Opponents Want the Record Reopened
The request came from DUID Victim Voices, physician Kenneth Finn and the National Drug and Alcohol Screening Association, three participants opposed to broader rescheduling. They sought to introduce the report and submit additional arguments concerning its effect on the case. Their position is that the reliability of the government’s conclusion depends partly on the process used to reach it. They argue that deficiencies in written evaluation criteria deserve attention before the tribunal accepts the government’s case for changing marijuana’s classification. That is a challenge to the foundation of the recommendation, alongside the substantive disagreements already aired during the hearing.
The distinction between an opponent’s argument and an adjudicated finding is essential here. Julius found a pause warranted while considering the motion; that procedural judgment does not establish that the asserted deficiencies invalidate the proposal. An audit can identify a genuine management problem without proving that every decision affected by the process is wrong. Conversely, favorable historical outcomes do not answer every question about whether a particular evaluation was sufficiently supported. The coming responses will give the government and other participants an opportunity to explain where the report bears directly on the existing record and where its findings address broader agency administration.
The Government Still Defends Schedule III
DEA’s position in the hearing is to defend the proposed transfer, rather than simply oppose a change to marijuana’s status. In its post-hearing brief, the agency argued that marijuana no longer meets Schedule I requirements because it has a currently accepted medical use and accepted safety under medical supervision. It also maintained that the evidence concerning abuse and dependence better supports Schedule III than the more restrictive classifications. Those assertions form the government’s affirmative case. The September stay does not replace that case with a contrary agency conclusion, and the request for new briefing does not itself withdraw the proposal.
Understanding the dispute requires separating medical usefulness from an assertion that cannabis carries no risks. Federal scheduling accommodates substances that have accepted medical uses while remaining controlled because of abuse or dependence concerns. Evidence of risk therefore remains relevant, but risk alone does not resolve which schedule is appropriate. The central inquiry is how the statutory findings apply to the substance and the evidence before the agency. A proceeding framed solely as a contest between claims that marijuana is harmless and claims that it is dangerous would miss the legal question the government and opposing participants must actually address.
Medical Use and FDA Approval Are Different Questions
The Controlled Substances Act ties Schedule I to a high potential for abuse, no currently accepted medical use in the United States and a lack of accepted safety under medical supervision. Schedule III requires accepted medical use, an abuse potential lower than substances in Schedules I and II, and specified dependence findings. The law also calls for consideration of eight factors, including pharmacological effects, scientific knowledge, patterns of abuse, public-health risks and dependence. Medical use is therefore central, but it is one part of a classification decision that must account for the statutory framework as a whole.
The Justice Department’s Office of Legal Counsel addressed the medical-use issue in an April 2024 opinion. It concluded that DEA’s longstanding approach was too narrow and that HHS’s newer framework could establish accepted medical use without FDA approval or satisfaction of DEA’s older five-part test. That framework considers widespread medical practice under authorized programs and credible scientific support for a recognized use. The legal distinction is consequential: deciding that a substance has an accepted medical use for scheduling purposes is different from approving a specific finished medicine for sale. Broader rescheduling would not itself confer FDA approval on every cannabis product offered in a dispensary.
April’s Medical Marijuana Action Remains Separate
The current case concerns broader rescheduling, but it is unfolding against a federal framework that already changed earlier this year. On April 23, the Justice Department announced an order placing FDA-approved marijuana products and marijuana products subject to qualifying state medical marijuana licenses in Schedule III. At the same time, the administration launched a new hearing process to consider a more comprehensive transfer. Those actions created separate legal tracks: an issued medical marijuana order and a continuing proceeding over the broader proposal. Describing every form of marijuana as still awaiting its first federal reclassification would overlook that distinction.
The September 29 stay addresses the pending hearing; it does not purport to reverse the separate April order. That matters when interpreting headlines suggesting that all marijuana reform has stopped or that previously issued medical provisions have disappeared. The April rule also retained controls and left marijuana outside its covered categories in Schedule I. For patients, providers and businesses, the relevant questions consequently depend on which products and activities are involved. A procedural delay in broader rescheduling cannot be treated as a single answer covering the entire medical market, adult-use market and federal regulatory system.
Why the Delay Matters for Cannabis Businesses
Broader Schedule III treatment carries potential financial significance because Section 280E of the Internal Revenue Code denies deductions for businesses trafficking in Schedule I or II controlled substances. The government’s 2024 proposal identified removal of that statutory barrier as a potential consequence of a completed transfer. For activities still involving Schedule I marijuana, a delay keeps the broader change unsettled. Yet the April medical rule has already introduced a separate set of tax and regulatory considerations for qualifying licensees. The new stay therefore does not mean that every cannabis business has the same tax position or faces an identical set of consequences.
Beyond taxation, uncertain timing complicates planning. Businesses considering financing, expansion or restructuring have an interest in knowing which federal rules will apply and when. Researchers likewise have reason to distinguish a proposed classification from an effective one, since scheduling affects the regulatory conditions under which work proceeds. None of those practical stakes makes a judge’s recommendation equivalent to nationwide commercial legalization. The proposal itself contemplates continued federal controls, and a schedule change would not automatically authorize every existing transaction. The value of a reliable timetable lies in allowing decisions to follow an actual legal change rather than expectations about a pending case.
The Next Decision Is About the Record
The most immediate development to watch is the government’s October response and Julius’s subsequent ruling on the motion. He could decline to add the report, admit it with an opportunity for further briefing or otherwise address the request within the proceeding. Those are possible procedural paths, not announced outcomes. The September order supplies no final rescheduling deadline. Anyone predicting completion before a particular political or business milestone is therefore making a forecast beyond what the order establishes. The next ruling should clarify how, if at all, the newly published audit becomes part of the tribunal’s assessment.
The pause brings an institutional issue into a debate usually dominated by medical evidence, criminal law and cannabis politics. Agencies need a defensible explanation of how they evaluate substances, and participants need a fair opportunity to address material added late in a case. At the same time, procedural criticism must be connected to the decision actually under consideration. That connection is now the contested question. The broader marijuana proposal remains pending, the government continues to defend Schedule III, and the judge has reserved judgment on whether the watchdog report warrants an expanded record before he completes his recommendation.
